VRDN

Viridian Therapeutics Inc

Sep 18 • 11:29AM ET

19.08

+0.46 2.47 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX EXEL SRPT BMRN ALNY RARE IONS ADAP PBYI

| Held by: VTI IWM XBI VXF IWO SCHA VTWO VHT IWC IWN

Index	RUT	P/E	-	EPS (ttm)	-4.27	Insider Own	9.93%	Shs Outstand	81.65M	Perf Week	-2.90%
Market Cap	1.56B	Forward P/E	-	EPS next Y	-4.04	Insider Trans	0.00%	Shs Float	73.55M	Perf Month	7.13%
Enterprise Value	1.21B	PEG	-	EPS next Q	-0.95	Inst Own	106.22%	Short Float	15.73%	Perf Quarter	27.20%
Income	-328.98M	P/S	5193.72	EPS this Y	-9.88%	Inst Trans	4.52%	Short Ratio	14.93	Perf Half Y	23.66%
Sales	0.30M	P/B	4.77	EPS next Y	2.50%	ROA	-56.33%	Short Interest	11.57M	Perf YTD	-0.47%
Book/sh	4.00	P/C	2.77	EPS next 5Y	19.51%	ROE	-62.99%	52W High	27.20 -29.85%	Perf Year	-11.50%
Cash/sh	6.90	P/FCF	-	EPS past 3/5Y	22.74% 31.28%	ROIC	-62.16%	52W Low	9.90 92.73%	Perf 3Y	-14.25%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-53.29% -41.64%	Gross Margin	-255.08%	Volatility	4.61% 5.30%	Perf 5Y	39.98%
Dividend TTM	-	EV/Sales	4022.25	EPS Y/Y TTM	-0.36%	Oper. Margin	-121831.15%	ATR (14)	0.93	Perf 10Y	-94.03%
Dividend Ex-Date	-	Quick Ratio	11.01	Sales Y/Y TTM	5.90%	Profit Margin	-107863.61%	RSI (14)	54.08	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	11.01	EPS Q/Q	-21.30%	SMA20	0.80%	Beta	0.52	Target Price	39.13
Payout	-	Debt/Eq	0.04	Sales Q/Q	4.17%	SMA50	6.13%	Rel Volume	0.33	Prev Close	18.62
Employees	143	LT Debt/Eq	0.03	Earnings	Aug 06 BMO	SMA200	16.05%	Avg Volume	775.00K	Price	19.08
IPO	Jun 18, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.91% 47.35%	Trades		Volume	87,098	Change	2.47%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-25-25	Resumed	Jefferies	Buy	$44
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$37 → $27
Nov-25-24	Initiated	TD Cowen	Buy
Sep-11-24	Reiterated	Needham	Buy	$30 → $38
Jun-11-24	Initiated	Wolfe Research	Outperform	$29
Jun-06-24	Initiated	Goldman	Buy	$23
May-09-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
May-09-24	Downgrade	B. Riley Securities	Buy → Neutral	$25 → $20
Jun-14-23	Resumed	Credit Suisse	Outperform	$51
Jun-14-23	Initiated	BTIG Research	Buy	$46
May-30-23	Initiated	RBC Capital Mkts	Outperform	$44
Apr-17-23	Initiated	Wells Fargo	Overweight	$46
Mar-30-23	Initiated	Stifel	Buy	$49
Dec-19-22	Initiated	Needham	Buy	$45
Dec-19-22	Initiated	Cowen	Outperform	$45
Dec-16-22	Initiated	Credit Suisse	Outperform	$51
Dec-01-22	Initiated	H.C. Wainwright	Buy	$35
Jun-23-22	Initiated	B. Riley Securities	Buy	$25
Nov-18-21	Initiated	SVB Leerink	Outperform	$32
Oct-12-21	Initiated	Evercore ISI	Outperform	$40

Show Previous Ratings

Sep-15-25 07:01AM	Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates (Business Wire)
Sep-03-25 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-17-25 11:41PM	Viridian Therapeutics, Kissei Pharmaceutical Partner for Japanese Development of Thyroid Eye Disease Therapies, Securing $70M Upfront (Insider Monkey)
Aug-06-25 07:45AM	Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results (Business Wire)
07:00AM	Loading…
Aug-04-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-31-25 05:37AM	Viridian and Kissei to advance veligrotug and VRDN-003 in Japan (Pharmaceutical Technology)
Jul-30-25 08:30AM	Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval (BioPharma Dive) +6.02%
04:00AM	Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments (Business Wire)
Jul-15-25 08:58AM	Viridian Therapeutics' Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial (Insider Monkey) -5.13%
Jul-03-25 07:00AM	Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-05-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-30-25 07:00AM	Viridian Therapeutics to Participate in Upcoming June Investor Conferences (Business Wire)
May-20-25 07:00AM	Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) (Business Wire) +7.80%
May-07-25 04:15PM	Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) (Business Wire)
08:10AM	Loading…
May-06-25 08:10AM	Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -8.31%
07:00AM	Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results (Business Wire)
May-02-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-15-25 08:09AM	Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last? (Zacks)
Apr-07-25 07:00AM	Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors (Business Wire)
Mar-19-25 05:07PM	Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (SeekingAlpha)
Mar-10-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 07:00AM	Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-06-25 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-08-25 07:00AM	Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease (Business Wire) -8.42%
Dec-17-24 07:40AM	Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints (TipRanks)
Dec-16-24 04:09PM	Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen (Investor's Business Daily) +20.67%
09:28AM	Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease (Investor's Business Daily)
07:00AM	Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease (Business Wire)
Dec-13-24 06:00PM	Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 (Business Wire)
04:01PM	Loading…
Dec-04-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-12-24 07:00AM	Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data (Business Wire) -12.76%
Nov-05-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-24 11:25PM	Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock (Business Wire) +5.60%
Sep-10-24 04:01PM	Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock (Business Wire) +32.14%
07:00AM	Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (Business Wire)
Sep-09-24 04:01PM	Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024 (Business Wire)
Sep-05-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.23%
Aug-08-24 08:15AM	Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-07-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-28-24 09:09AM	Goldman Sachs Predicts up to 165% Surge for These 2 Strong Buy Stocks (TipRanks)
Jul-25-24 08:00AM	Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) (Business Wire)
Jul-08-24 10:38AM	3 Small-Cap Stocks With Explosive 2X Growth Potential (InvestorPlace)
Jul-03-24 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-27-24 09:48AM	Are Analysts Bullish on Viridian Therapeutics, Inc. (VRDN) Right Now? (Insider Monkey)
Jun-26-24 04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey)
Jun-12-24 09:11AM	Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug (Zacks) -5.94%
Jun-11-24 06:00AM	Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease (Business Wire) +10.15%
Jun-06-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-31-24 08:00AM	Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences (Business Wire)
May-10-24 08:00AM	Viridian Therapeutics to Participate in Upcoming May Investor Conferences (Business Wire)
May-09-24 03:02AM	Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com) -6.64%
May-08-24 11:54AM	VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:36AM	Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements (GuruFocus.com)
08:25AM	Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results (Business Wire)
May-03-24 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.62%
Apr-29-24 08:00AM	Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024 (Business Wire) +5.59%
Apr-04-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-06-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-05-24 08:00AM	Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference (Business Wire)
Feb-28-24 09:55AM	How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81% (Zacks)
Feb-27-24 04:01PM	Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-16-24 08:00AM	Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer (Business Wire)
Feb-06-24 04:01PM	Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-17-24 10:00PM	Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock (Business Wire) -9.73%
04:01PM	Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock (Business Wire)
Jan-08-24 08:00AM	Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference (Business Wire) +7.78%
Jan-04-24 08:00AM	Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-23 07:00AM	Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease (Business Wire) +9.52%
Nov-21-23 08:00AM	Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-13-23 05:00PM	Viridian Therapeutics Inc (VRDN) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com) +8.79%
04:01PM	Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (Business Wire)
Nov-08-23 08:00AM	Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference (Business Wire)
Nov-03-23 08:00AM	Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology (Business Wire) +7.88%
Oct-30-23 08:30AM	Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing (Business Wire) +5.17%
Oct-26-23 08:00AM	Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease (Business Wire) +8.57%
Sep-25-23 08:00AM	Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors (Business Wire)
Sep-07-23 08:00AM	Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September (Business Wire)
Aug-08-23 04:01PM	Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (Business Wire) +5.69%
Aug-04-23 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jul-10-23 04:01PM	Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) (Business Wire) +5.06% -16.39%
Jul-06-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jun-13-23 08:00AM	Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society (Business Wire)
Jun-05-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-23 04:01PM	Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-23 08:00AM	Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections (GlobeNewswire)
May-04-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-23 08:00AM	Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023 (GlobeNewswire)
Apr-20-23 01:41PM	UPDATE Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology (GlobeNewswire)
08:00AM	Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology (GlobeNewswire)
Apr-16-23 09:50AM	TipRanks Perfect 10 List: 2 Top-Rated Stocks Potentially Undervalued by ~90% (TipRanks)
Apr-13-23 06:52AM	Daily Vickers Top Buyers & Sellers for 04/13/2023 (Argus Research)
Apr-12-23 08:00AM	Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer (GlobeNewswire)
Apr-04-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-08-23 07:00AM	Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates (GlobeNewswire) -10.48%
Mar-07-23 08:00AM	Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society (GlobeNewswire)
Mar-03-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-23 08:00AM	Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023 (GlobeNewswire)
Feb-28-23 08:00AM	Viridian Therapeutics to Participate in Cowens 43rd Annual Health Care Conference (GlobeNewswire)

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fairmount Funds Management LLC	Director	Jun 10 '25	Option Exercise	12.31	12,500	153,875	3,459,913	Jun 11 05:00 PM
Fairmount Funds Management LLC	Director	Jun 09 '25	Option Exercise	7.80	1,600	12,480	3,447,413	Jun 11 05:00 PM
Beetham Thomas W.	Chief Operating Officer	Sep 27 '24	Buy	23.41	5,000	117,050	6,000	Sep 30 07:12 PM
Mahoney Stephen F.	President and CEO	Sep 27 '24	Buy	23.33	21,400	499,262	21,400	Sep 30 07:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VRDN

Viridian Therapeutics Inc

Upgrade your FINVIZ experience